Last reviewed 2026-05-15 · How we verify

Docetaxel + LH-RH analogues

Docetaxel inhibits microtubule depolymerization to arrest cancer cell division, while LH-RH analogues suppress testosterone production to reduce androgen-dependent tumor growth.

Docetaxel inhibits microtubule depolymerization to arrest cancer cell division, while LH-RH analogues suppress testosterone production to reduce androgen-dependent tumor growth. Used for Metastatic castration-sensitive prostate cancer, Hormone-sensitive prostate cancer.

At a glance

Mechanism of action

Docetaxel is a taxane chemotherapy agent that stabilizes microtubules and prevents their disassembly, leading to mitotic arrest and apoptosis in rapidly dividing cells. LH-RH (luteinizing hormone-releasing hormone) analogues suppress the hypothalamic-pituitary-gonadal axis, reducing circulating testosterone levels. This combination targets both the proliferative capacity of cancer cells and their hormonal dependence, particularly effective in hormone-sensitive malignancies.

Approved indications

• Metastatic castration-sensitive prostate cancer
• Hormone-sensitive prostate cancer

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Neuropathy (peripheral)
• Fatigue
• Nausea/vomiting
• Hot flashes (from LH-RH)
• Fluid retention
• Hypersensitivity reactions

Key clinical trials

• Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Docetaxel + LH-RH analogues CI brief — competitive landscape report
• Docetaxel + LH-RH analogues updates RSS · CI watch RSS
• University of Turin, Italy portfolio CI